Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3

Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targetin

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (As

Additional Results from ACACIA-HCM Demonstrate Improvements in  Cardiac Structure and Diastolic Func

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Afic

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annuali

Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating a

Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly impro

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant

The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progre

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: C

Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises th

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises

In the complaint, the Company requests, among other things: a judgment declaring that the Company do

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy an

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lo

Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform an

Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the pri

Cytokinetics, Incorporated (CYTK) Q2 2026 Earnings Call Transcript

Cytokinetics NASDAQ: CYTK reported second-quarter results marked by early commercial momentum for MY

Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Esti

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst con

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annuali

Britain's medicines regulator approved Cytokinetics' drug for a rare heart condition on Thursday, wi

At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance re

Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics an

Cytokinetics (CYTK) is positioned to expand MYQORZO across the entire HCM continuum, not just as a l

SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: C

Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is ref

The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. W

The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represent

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lo

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the p

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced a call for proposals for its annual Cytokin

European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01,

Citigroup analyst Eric Joseph initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the presentation of new data reinforcing th

HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy

Wells Fargo analyst Yanan Zhu maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises t

Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and ra

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and ra